Volume | 300,673 |
|
|||||
News | - | ||||||
Day High | 11.10 | Low High |
|||||
Day Low | 10.76 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
iTeos Therapeutics Inc | ITOS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
10.80 | 10.76 | 11.10 | 10.99 | 10.79 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,235 | 300,673 | $ 10.91 | $ 3,279,458 | - | 8.20 - 18.24 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:02:20 | priorref | 533 | $ 10.99 | USD |
iTeos Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
394.63M | 35.84M | - | 12.6M | -112.64M | -3.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
iTeos Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ITOS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.69 | 11.69 | 10.01 | 10.61 | 329,827 | -0.70 | -5.99% |
1 Month | 11.71 | 13.80 | 10.01 | 12.23 | 321,056 | -0.72 | -6.15% |
3 Months | 10.58 | 13.80 | 9.70 | 11.32 | 285,928 | 0.41 | 3.88% |
6 Months | 8.79 | 13.80 | 8.70 | 10.72 | 304,627 | 2.20 | 25.03% |
1 Year | 13.75 | 18.24 | 8.20 | 11.79 | 361,774 | -2.76 | -20.07% |
3 Years | 23.92 | 52.43 | 8.20 | 21.52 | 364,347 | -12.93 | -54.06% |
5 Years | 19.70 | 52.43 | 8.20 | 22.66 | 332,987 | -8.71 | -44.21% |
iTeos Therapeutics Description
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. |